Stocktoria

BioAtla, Inc. BCAB

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-16

BioAtla, Inc. statistics & valuation

Market cap$6.1M

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-32146.70% 202020212022202320242025
Return on equity (%)
-17.10% -45.30% -59.00% -174.70% -489.10% 202020212022202320242025
Shares outstanding
32.2M 35.8M 46.3M 48.1M 58.1M 58.8M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-14.60% -37.50% -47.20% -103.20% -133.10% -431.10% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$2.76 -$2.74 -$2.58 -$1.44 -$1.01 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin————-32146.7%—
Net margin————-31800.7%—
Return on assets-431.1%-133.1%-103.2%-47.2%-37.5%-14.6%
Return on equity164.7%-489.1%-174.7%-59.0%-45.3%-17.1%
Current ratio0.373.524.119.5312.487.46

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.